Hospital A.C.Camargo

Oncologia Pediátrica

Período:  17/11/2009 a 17/12/2009
Dia(s) da Semana:  Terças, Quartas e Quintas-feiras
Horário:  08h00 às 12h00
Carga Horária Total: 48
Duração em semanas: 04 semanas
Local:  Auditório Dr. Humberto Torloni
Créditos:  05
Professor (es):- Dra. Beatriz de Camargo

Objetivo do curso: 

Transmitir aos alunos conceitos básicos sobre epidemiologia, genética, abordagem diagnóstica, princípios de tratamento e perspectivas atuais dos tumores infantis. Importância, planejamento e análise de ensaios clínicos.

Bibliografia:

• Gatta G, Capocaccia R, Coleman MP, Ries LAG, Berrino F. Childhood Cancer Survival in Europe and the United States. American Cancer Society 2002; 95:1767-72.
• *Moyer VA, Gist AK, Elliott EJ. Is the Practice of Paediatric Inpatient Medicine Evidence-Based? J Paediatric Child Health 2002; 38:347-351
• *Henry RL. Is Evidence in the Eyes of the Beholder? [Editorial] J Paediatric Child Health 2002; 38:341-352
• *McNally RJQ, Kelsey AM, Eden OB, Alexander FE, Cairns DP, Birch JM. Space-Time Clustering Patterns in Childhood Solid Tumours Other Than Central Nervous System Tumours. Int J Cancer 2002; 103:253-528
• *Li FP, Dreyfus MG, Russell TL, Verselis SJ, Hutchinson RJ, Fraumeni Jr. JF. Molecular Epidemiology Study of a Suspected Community Cluster of Childhood Cancers. Medical and Pediatric Oncology 1997; 28:243-247
• *Infante-Rivard C, Deadman JE. Maternal Occupational Exposure to Extremely Low Frequency Magnetic Fields During Pregnancy and Childhood Leukemia. Epidemiology 14(4):437-441
• *Keller M, Weis J, Schumacher A, Griessmeier B. Psycho-Oncology in a United Europe - Changes and Challenges. Crit Rev Oncol Hematology 2003; 45:109-117.
• *Norman AV, Richards SM, Martineau M, et al. Outcome Heterogeneity in Childhood High Hyperdiploid Acute Lymphoblastic Leukemia. Blood 2003
• *Campbell PJ, Morley AA. Modelling a Minimal Residual Disease-Based Treatment Strategy in Childhood Acute Lymphoblastic Leukaemia. Brit J Haematology 2003; 122:30-38.
• *Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T. The Wilms Tumor Supressor Gene WT1 Induces G1 Arrest and Apoptosis in Myeloblastic Leukemia M1 Cells. FEBS 1997; 409:41-45.
• *Vorwerk P, Wex H, Bessert C, Hohmann B, Schmidt U, Mittler U. Loss of Imprinting of IGF-II Gene in Children with Acute Lymphoblastic Leukemia. Leukemia Res 2003; 27:807-812.
• *Minicucci EM, Lopes LF, Crocci AJ. Dental Abnormalities in Children After Chemotherapy Treatment for Acute Lymphoid Leukemia. Leukemia Res 2003; 27:45-50.
• *Raetz E, Perkis S, Davenport V, Cairo MS. B Large-Cell Lymphoma in Children and Adolescents. Cancer Treatment Reviews 2003; 29:91-98.
• *Cairo MS, Sposto R, Perkins SL, et al. Burkitt´s and Burkitt-like Lymphoma in Children and Adolescents: a Review of the Children´s Cancer Group Experience. Brit J Haematol. 2003; 120:660-670.
• *Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-Induced Hearing Loss in Patients with Malignant Brain Tumors. Clin Cancer Res 2001; 7:493-500.
• *Cairo MS, Sposto R, Hoover-Regan M, et al. Childhood and Adolescent Large-Cell Lymphoma (LCL): A Review of the Children´s Cancer Group Experience. Am J Hematol 2003; 72:53-60.
• *Thomson AB, Wallace WHB. Treatment of Paediatric Hodgkin´s Disease: a Balance of Risks. Eur J Cancer 2002; 38:468-477
• *Donaldson SS. Pediatric Hodgkin´s Disease - UP, UP, and Beyond. Int J Rad Oncol Biol Phys 2002; 54(1):1-8
• *Dieckmann K, Pötter R, Hofmann J, et al. Does Bulky Disease at Diagnosis Influence Outcome in Childhood Hodgkin´s Disease and Require Higher Radiation Doses? Results from the German-Austrian Pediatric Multicenter Trial Dal-HD-90. Int J Rad Oncol Biol Phys 2003; 56(3):644-652.
• *Langagergaard V, Norgard B, Mellenkjaer L, et al. Seasonal Variation in Month of Birth and Diagnosis in Children and Adolescents with Hodgkin Disease and Non-Hodgkin Lymphoma. J Pediatric Hematology/Oncology 2003; 25(7):534-538.
• *Cecchetto G, Bisogno G, Treuner J, et al. Role of Surgery for Nonmetastatic Abdominal Rhabdomyosarcomas. Cancer 2003; 97:1974-80.
• *Komdeur R, Klunder J, Graaf WTA, et al. Multidrug Resistance Proteins in Rhabdomyosarcomas. Cancer 2003; 97:1999-2005.
• *Ferrari A, Casanova M, Bisogno G, et al. Rhabdomyosarcoma in Infants Younger than One Year Old. Cancer 2003; 97:2597-604.
• *Paulino AC, Simon JH, Zhen W, Wen B-Chen. Long-Term Effects in Children Treated with Radiotherapy for Head and Neck Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2000; 48(5):1489-1495.
• *Estilo CL, Huryn JM, Kraus DH, et al. Effects of Therapy on Dentofacial Development in Long- Term Survivors of Head and Neck Rhabdomyosarcoma: The Memorial Sloan-Kettering Cancer Center Experience. J Pediatric Hematology/Oncology 2003; 25(3): 215-222.
• *Schalow EL, Broecker BH. Role of Surgery in Children with Rhabdomyosarcoma. Med Pediatr Oncol 2003; 41:1-6.
• *Eggert A, Ikegaki N, Kwiatkowski J, et al. High-Level Expression of Angiogenic Factors is Associated with Advanced Tumor Stage in Human Neuroblastomas. Clin Cancer Res 2000; 6:1900-1908.
• *Ribatti D, Vacca A, Nico B, et al. Angiogenesis and Anti-Angiogenesis in Neuroblastoma. Eur J Cancer 2002; 38:750-757.
• *Matthay KK, Edeline V, Lumbroso J, et al. Correlation of Early Metastatic Response by I-Metaiodobenzylguanidine Scintigraphy with Overall Response and Event-Free Survival in Stage IV Neuroblastoma. J Clin Oncol 2003; 21:2486-2491.
• *Brodeur GM. Neuroblastoma: Biological Insights Into a Clinical Enigma. Nature Rev Canc 2003; 3:203-216.
• *Tanaka K, Granata C, Wang Y, O´Briain DS, Puri P. Apoptosis and bcl-2 Oncogene Expression in Wilms´ Tumor. Pediatr Surg Int 1999; 15:243-247.
• *von Essen L, Enskar K, Haglund K, Hedstrom M, Skolin I. Important Aspects of Care and Assistance for Children 0-7 Years of Age Being Treated for Cancer. Parent and Nurse Perceptions. Support Care Cancer 2002; 10:601-612.
• *Ramachandran C, Melnick SJ, Escalon E, et al. Expression of Apoptosis, Cell Proliferation, and Drug Resistance Genes in Pediatric Wilms´Tumors. Anticancer Res 2000; 20:3759-3766.
• *Ghanem MA, Van der Kwast TH, Den Hollander JC, et al. The Prognostic Significance of Apoptosis-Associated Proteins BCL-2, BAX and BCL-X in Clinical Nephroblastoma. Brist J Cancer 2001; 85(10):1557-1583
• *Hawkins DS, Rajendran JG, Conrad EU, Bruckner JD, Eary JF. Evaluation of Chemotherapy Response in Pediatric Boné Sarcomas By [F-18]-Fluorodeoxy-D-Glucose Positron Emission Tomography. Cancer 2002; 94:3277-84
• *Amiel A, Ohali A, Fejgin M, Sardos-Albertini F, Bouaron N, Cohen IJ, Yaniv I, Zaizov R, Avigad S. Molecular Cytogenetic Parameters in Ewing Sarcoma. 2003; 140:107-112.
• *Trieb K, Lehner R, Stulnig T, Sulzabacher I, Shroyer R. Survivin Expression in Human Osteosarcoma is a Maker for Survival. EJSO 2003; 29:379-382.
• *Dagher R, Pham TA, Sorbara L, et al. Molecular Confirmation of Ewing Sarcoma. J Ped Hematology/Oncology 2001; 23(4):221-224.
• *Patiño-García A, Piñeiro ES, Díez MZ, et al. Genetic and Epigenetic Alterations of the Cell Cycle Regulators and Tumor Supressor Genes in Pediatric Osteosarcomas. J Ped Hematology/Oncology 2003; 25(5):362-367.
• *Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb Salvage and Amputation in Survivors of Pediatric Lower-Extremity Bone Tumors: What Are the Long-Term Implications? J Clin Oncol 2002; 20(22):4493-4501.
• *Kager L, Zoubek A, Potschger U, et al. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol 2003; 21(1):2011-2018.
• *Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities. J Clin Oncol 2003; 21(3):536-542.
• *Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival. J Clin Oncol 2003; 21(4):710-715.
• *Schleiermarcher G, Peter M, Oberlin O, et al. Increased Risk of Systemic Relapses Associated with Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor. J Clin Oncol 2003; 21(1):85-91.
• *Langeveld NE, Stam H, Grotenhuins MA, Last BF. Quality of Life in Young Adult Survivors of Childhood Cancer. Support Care Cancer 2003; 10:579-600.
• *Gerharz EW, Eiser C, Woodhouse CRJ. Current Approaches to Assessing the Quality of Life in Children and Adolescents. BJU Inter 2003; 91:150-154.
• *Nagarajan R, Neglia JP, Clohisy DR. Education, Employment, Insurance, and Marital Status Among 694 Survivors of Pediatric Lower Extremity Bone Tumors. A Report from the Childhood Cancer Survivor Study. Cancer 2003; 97:2554-64.
• *Eliser C, Vance YH, Horne B, Glaser A, Galvin H. The Value of the PedsQLTM in Assessing Quality of Life in Survivors of Childhood Cancer. 2003; 29(2):95-102.
• *Shusterman S, Meadows AT. Long Term Survivors of Childhood Leukemia. Curr Opin Hematol 2000; 7:217-222.
• *Noorda EM, Somers R, van Leeuwen FE, et al. Adult Height and Age at Menarche in Childhood Cancer survivors. Eur J Canc 2001; 37:605-612.
• *Waters EB, Wake MA, Hesketh KD, et al. Health-Related Quality of Life of Children with Acute Lymphoblastic Leukaemia: Comparisons and Correlations Between Parent and Clinician Reports. Int J Cancer 2003; 103:514-518.
• *Brown PD, Buckner JC, O´Fallon JR, et. al. Effects of Radiotherapy on Cognitive Function in Patients with Low-Grade Glioma measured by the Folstein Mini-Mental State Examination. J Clin Oncol 2003; 21:2519-2524.
• *Shanafelt T, Adjei A, Meyskens FL. When Your Favorite Patient Relapses: Physician Grief and Well-Being in the Practice of Oncology. J Clin Oncol 2003; 21(13):2616-2619.
• *Barr RD, Chalmers D, Pauw SD, et al. Health-Related Quality of Life in Survivors of Wilms´ Tumor and Advanced Neuroblastoma: A Cross-Sectional Study. J Clin Oncol 2000; 18(18):3280-3287.
• *Ganz PA. Late Effects of Cancer and Its Treatment. Seminars in Oncology Nursing 2001; 17(4):241-248.

Informações gerais: 

Todos os cursos a serem ministrados estão sujeitos à mudança de local e data.